EOLS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EOLS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Evolus's gross profit for the three months ended in Sep. 2024 was $42.9 Mil. Evolus's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was $173.7 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Evolus's gross profit for the three months ended in Sep. 2024 was $42.9 Mil. Evolus's Revenue for the three months ended in Sep. 2024 was $61.1 Mil. Therefore, Evolus's Gross Margin % for the quarter that ended in Sep. 2024 was 70.17%.
Evolus had a gross margin of 70.17% for the quarter that ended in Sep. 2024 => Durable competitive advantage
During the past 9 years, the highest Gross Margin % of Evolus was 77.05%. The lowest was 56.32%. And the median was 67.64%.
The historical data trend for Evolus's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evolus Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Gross Profit | Get a 7-Day Free Trial | 26.91 | 38.24 | 56.14 | 92.73 | 140.53 |
Evolus Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Gross Profit | Get a 7-Day Free Trial | 34.59 | 41.73 | 41.27 | 47.83 | 42.86 |
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Evolus's Gross Profit distribution charts can be found below:
* The bar in red indicates where Evolus's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Evolus's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit (A: Dec. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 202.085 | - | 61.559 | |
= | 140.5 |
Evolus's Gross Profit for the quarter that ended in Sep. 2024 is calculated as
Gross Profit (Q: Sep. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 61.085 | - | 18.223 | |
= | 42.9 |
Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $173.7 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Evolus's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as
Gross Margin % (Q: Sep. 2024 ) | = | Gross Profit (Q: Sep. 2024 ) | / | Revenue (Q: Sep. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 42.9 | / | 61.085 | |
= | 70.17 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Evolus (NAS:EOLS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Evolus had a gross margin of 70.17% for the quarter that ended in Sep. 2024 => Durable competitive advantage
Thank you for viewing the detailed overview of Evolus's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Sandra Beaver | officer: Chief Financial Officer | 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660 |
Tomoko Yamagishi-dressler | officer: Chief Marketing Officer | 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660 |
David Moatazedi | director, officer: See Remarks | C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008 |
Vikram Malik | director | 17901 VON KARMAN AVENUE, SUITE 150, IRVINE CA 92614 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Rui Avelar | officer: See Remarks | 1618 STATION STREET, VANCOUVER A1 V6A 1B6 |
Karah Herdman Parschauer | director | 60 LEVERONI COURT, NOVATO CA 94949 |
Medytox Inc. | 10 percent owner | 78, GANGNI 1-GIL, OCHANG-EUP,, CHEONGWON-GU, CHEOGJU-SI M5 28126 |
Alphaeon 1 Llc | 10 percent owner | 4040 MACARTHUR BOULEVARD, SUITE 310, NEWPORT BEACH CA 92660 |
Robert Hayman | director | 8550 HIGUERA ST, CULVER CITY CA 90232 |
Simone Blank | director | C/O SIRONA, WASSERFELDSTRASSE 30 A-5020, SALZBURG C4 5020 |
Peter C Farrell | director | RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
Lauren P Silvernail | officer: See Remarks | 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618 |
Crystal Muilenburg | officer: Chief Marketing Officer | 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660 |
Brady Stewart | director | 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH CA 92660 |
From GuruFocus
By Business Wire • 10-23-2024
By Business Wire • 11-06-2024
By Business Wire • 10-29-2024
By Business Wire • 10-31-2024
By GuruFocus News • 10-09-2024
By GuruFocus Research • 09-12-2024
By GuruFocus News • 11-07-2024
By Business Wire • 07-30-2024
By Business Wire • 07-17-2024
By GuruFocus News • 11-28-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.